Q1 2024 Earnings Call Transcript May 14, 2024 Operator: Good afternoon, everyone. And welcome to the NRx Pharmaceuticals, Inc. First Quarter of 2024 Results Conference Call [Operator Instructions]. As ...

Significant financial improvements and advances in clinical trials mark NRX Pharmaceuticals Inc's first quarter of 2024.

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) Q1 2024 Earnings Call Transcript May 9, 2024 Collegium Pharmaceutical, Inc.

NRx Pharmaceuticals (Nasdaq: NRXP) recently shared its financials and offered updates on its business operations from the ...

Good afternoon, everyone, and welcome to the NRx Pharmaceuticals, Inc. first quarter of 2024 results conference call. Currently, all participants are on a listen-only mode. As a reminder, this ...

Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor ...

In the United States, noroviruses are the single most common cause of acute gastroenteritis in adults that results in a visit to the hospital emergency department, and they are second only to ...

Noroviruses are a frequent cause of both acute gastroenteritis and outbreaks of gastroenteritis. Infection is usually self-limiting although it has been associated with mortality in children in ...